Acer Medical (6857) H1 2025 earnings summary

Executive summary

• Revenue for the first half of 114 year reached NT$30,121 thousand, up from NT$25,178 thousand year-over-year.

• Net loss widened to NT$15,144 thousand from NT$12,186 thousand year-over-year.

• Gross margin decreased to 61% from 68% year-over-year.

• No dividends distributed due to continued losses.

Financial highlights

• Operating expenses increased to NT$34,861 thousand from NT$30,759 thousand year-over-year.

• Basic and diluted loss per share were NT$0.99, compared to NT$0.80 year-over-year.

• Cash and cash equivalents at period end were NT$182,274 thousand, down from NT$202,777 thousand at prior year-end.

• Net cash outflow from operating activities was NT$19,438 thousand, compared to NT$16,518 thousand year-over-year.

Outlook and guidance

• The company continues to focus on AI and big data analytics for smart healthcare, expanding product integration into medical care and international markets.

• Ongoing evaluation of new IFRS standards and their impact on financial reporting.